Co-occurrence of early diabetes-related complications in adolescents and young adults with type 1 diabetes: an observational cohort study.


Journal

The Lancet. Child & adolescent health
ISSN: 2352-4650
Titre abrégé: Lancet Child Adolesc Health
Pays: England
ID NLM: 101712925

Informations de publication

Date de publication:
01 2019
Historique:
received: 17 08 2018
revised: 14 09 2018
accepted: 17 09 2018
pubmed: 10 11 2018
medline: 7 5 2020
entrez: 10 11 2018
Statut: ppublish

Résumé

One in three adolescents and young adults with type 1 diabetes have at least one early diabetes-related complication or comorbidity. We aimed to examine the prevalence and pattern of co-occurring complications in this population, as well as the related risk factors. This observational cohort study includes data from individuals diagnosed with type 1 diabetes before age 20 years who participated in the SEARCH for Diabetes in Youth Study across five sites in the USA. We assessed sociodemographic and metabolic risk factors at baseline and at follow-up, and diabetes complications at follow-up. A frequency analysis was done to examine the difference in observed versus expected prevalence (calculated using a contingency table assuming independence across cells) of co-occurring complications or comorbidities. A cluster analysis was done to identify unique clusters of participants based on demographic characteristics and metabolic risk factors. 1327 participants who completed the follow-up visit were included in the frequency analysis. The mean age was 10·1 (SD 3·9) years at the time of type 1 diabetes diagnosis and 18·0 (4·1) years at follow-up. At a mean diabetes duration of 7·8 [SD 1·9] years, co-occurrence of any two or more complications was observed in 78 (5·9%) participants, more frequently than expected by chance alone (58 [4·4%], p=0·015). Specifically, the complications that co-occurred more frequently than expected were retinopathy and diabetic kidney disease (11 [0·8%] vs three [0·2%]; p=0·0007), retinopathy and arterial stiffness (13 [1·0%] vs four [0·3%]; p=0·0016), and arterial stiffness and cardiovascular autonomic neuropathy (24 [1·8%] vs 13 [1·0%]; p=0·015). We identified four unique clusters characterised by progressively worsening metabolic risk factor profiles (longer duration of diabetes and higher glycated haemoglobin, non-HDL cholesterol, and waist-to-height ratio). The prevalence of at least two complications increased across the clusters (six [2·3%] of 261 in the low-risk cluster, 32 [6·3%] of 509 in the moderate-risk cluster, 28 [8%] of 348 in the high-risk cluster, and five [20·8%] of 24 in the highest-risk cluster). Compared with the low-risk and moderate-risk clusters, the high-risk and highest-risk clusters were characterised by a lower proportion of participants who were non-Hispanic white, and a higher proportion of participants who had a household income below US$50 000 and did not have private health insurance. Early complications co-occur in adolescents and young adults with type 1 diabetes more frequently than expected. Identification of individuals with adverse risk factors could enable targeted behavioural or medical interventions that reduce the likelihood of early development of lifelong diabetes-related morbidity. US Centers for Disease Control and Prevention, US National Institutes of Health.

Sections du résumé

BACKGROUND
One in three adolescents and young adults with type 1 diabetes have at least one early diabetes-related complication or comorbidity. We aimed to examine the prevalence and pattern of co-occurring complications in this population, as well as the related risk factors.
METHODS
This observational cohort study includes data from individuals diagnosed with type 1 diabetes before age 20 years who participated in the SEARCH for Diabetes in Youth Study across five sites in the USA. We assessed sociodemographic and metabolic risk factors at baseline and at follow-up, and diabetes complications at follow-up. A frequency analysis was done to examine the difference in observed versus expected prevalence (calculated using a contingency table assuming independence across cells) of co-occurring complications or comorbidities. A cluster analysis was done to identify unique clusters of participants based on demographic characteristics and metabolic risk factors.
FINDINGS
1327 participants who completed the follow-up visit were included in the frequency analysis. The mean age was 10·1 (SD 3·9) years at the time of type 1 diabetes diagnosis and 18·0 (4·1) years at follow-up. At a mean diabetes duration of 7·8 [SD 1·9] years, co-occurrence of any two or more complications was observed in 78 (5·9%) participants, more frequently than expected by chance alone (58 [4·4%], p=0·015). Specifically, the complications that co-occurred more frequently than expected were retinopathy and diabetic kidney disease (11 [0·8%] vs three [0·2%]; p=0·0007), retinopathy and arterial stiffness (13 [1·0%] vs four [0·3%]; p=0·0016), and arterial stiffness and cardiovascular autonomic neuropathy (24 [1·8%] vs 13 [1·0%]; p=0·015). We identified four unique clusters characterised by progressively worsening metabolic risk factor profiles (longer duration of diabetes and higher glycated haemoglobin, non-HDL cholesterol, and waist-to-height ratio). The prevalence of at least two complications increased across the clusters (six [2·3%] of 261 in the low-risk cluster, 32 [6·3%] of 509 in the moderate-risk cluster, 28 [8%] of 348 in the high-risk cluster, and five [20·8%] of 24 in the highest-risk cluster). Compared with the low-risk and moderate-risk clusters, the high-risk and highest-risk clusters were characterised by a lower proportion of participants who were non-Hispanic white, and a higher proportion of participants who had a household income below US$50 000 and did not have private health insurance.
INTERPRETATION
Early complications co-occur in adolescents and young adults with type 1 diabetes more frequently than expected. Identification of individuals with adverse risk factors could enable targeted behavioural or medical interventions that reduce the likelihood of early development of lifelong diabetes-related morbidity.
FUNDING
US Centers for Disease Control and Prevention, US National Institutes of Health.

Identifiants

pubmed: 30409691
pii: S2352-4642(18)30309-2
doi: 10.1016/S2352-4642(18)30309-2
pmc: PMC6295346
mid: NIHMS1511858
pii:
doi:

Types de publication

Journal Article Observational Study Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

35-43

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK057516
Pays : United States
Organisme : NIDDK NIH HHS
ID : UC4 DK108173
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U01 DP000247
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U18 DP002710
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U18 DP006134
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000154
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U18 DP002714
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U01 DP000248
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U01 DP000244
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000062
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U18 DP002709
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK056350
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000077
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000423
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U01 DP000250
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U18 DP002708
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK017047
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001425
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002319
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U01 DP000246
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U01 DP000254
Pays : United States

Investigateurs

Maryam Afkarian (M)
James Amrhein (J)
Natalie Beauregard (N)
Ronny Bell (R)
Anna Bellatorre (A)
Clifford A Bloch (CA)
Deborah Bowlby (D)
Ralph D'Agostino (R)
Dana Dabelea (D)
Stephen Daniels (S)
Jasmin Divers (J)
Lawrence M Dolan (LM)
Vinod P Gaur (VP)
Maureen T Goldstein (MT)
Carla Greenbaum (C)
Richard F Hamman (RF)
Jessica Harting (J)
Leora Henkin (L)
Irl Hirsch (I)
Kim Holmquist (K)
Giuseppina Imperatore (G)
Scott Isom (S)
Malaka Jackson (M)
Michael G Kahn (MG)
Sue Kearns (S)
Grace Kim (G)
Georgeanna J Klingensmith (GJ)
Mary Klingsheim (M)
Lisa Knight (L)
Corinna Koebnick (C)
Jean M Lawrence (JM)
Xia Li (X)
Angela D Liese (AD)
Barbara Linder (B)
Lenna L Liu (LL)
Beth Loots (B)
Kathy Love-Osborne (K)
David Maahs (D)
Santica M Marcovina (SM)
Elizabeth J Mayer-Davis (EJ)
Anwar Merchant (A)
Lina Merjaneh (L)
Timothy Morgan (T)
Amy Mottl (A)
Debika Nandi-Munshi (D)
John Neff (J)
Bryce Nelson (B)
Michael Pascual (M)
David J Pettitt (DJ)
June Pierce (J)
Catherine Pihoker (C)
Jeffrey Powell (J)
Beth Reboussin (B)
Marian J Rewers (MJ)
Kristi Reynolds (K)
Katherine A Sauder (KA)
Sharon H Saydah (SH)
Jeanette Stafford (J)
Debra A Standiford (DA)
Greg Strylewicz (G)
Craig Taplin (C)
Lisa Testaverde (L)
Joan Thomas (J)
Paul Wadwa (P)
Lynne E Wagenknecht (LE)
Greta Wilkening (G)
Carrie Williams (C)
Davene Wright (D)
Joyce Yi-Frazier (J)

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

Diabet Med. 2000 Feb;17(2):146-51
pubmed: 10746486
J Diabetes Complications. 2000 Nov-Dec;14(6):295-300
pubmed: 11120452
Adv Data. 2000 Jun 8;(314):1-27
pubmed: 11183293
AMA Arch Intern Med. 1954 Dec;94(6):931-41
pubmed: 13217491
Diabetes Care. 2005 Jul;28(7):1649-55
pubmed: 15983315
Exp Clin Endocrinol. 1992;99(2):102-7
pubmed: 1639116
J Pediatr Endocrinol Metab. 2006 Jan;19(1):45-54
pubmed: 16509528
Diabet Med. 2006 Aug;23(8):857-66
pubmed: 16911623
Diabetes Care. 2007 Oct;30(10):2523-8
pubmed: 17630266
J Clin Endocrinol Metab. 2010 Jul;95(7):3360-7
pubmed: 20444913
Ophthalmic Epidemiol. 2010 Aug;17(4):251-65
pubmed: 20642348
Diabetologia. 2011 Jan;54(1):78-86
pubmed: 20886205
Ann Med. 2012 Mar;44(2):196-204
pubmed: 21047152
Diabetes Care. 2011 Jul;34(7):1628-33
pubmed: 21636800
Clin Chem. 2011 Dec;57(12):1693-702
pubmed: 21980171
Diabetes Care. 2013 Aug;36(8):2351-8
pubmed: 23435158
Curr Diab Rep. 2013 Dec;13(6):814-23
pubmed: 24037313
J Clin Res Pediatr Endocrinol. 2013 Sep 10;5(3):145-9
pubmed: 24072081
JAMA. 2014 May 7;311(17):1778-86
pubmed: 24794371
Curr Diab Rep. 2015 Sep;15(9):57
pubmed: 26188736
Can J Diabetes. 2016 Jun;40(3):258-63
pubmed: 26976719
Lancet Diabetes Endocrinol. 2016 Jul;4(7):588-97
pubmed: 27216886
Diabetes Care. 2017 Jan;40(Suppl 1):S88-S98
pubmed: 27979897
JAMA. 2017 Feb 28;317(8):825-835
pubmed: 28245334
N Engl J Med. 2017 Apr 13;376(15):1419-1429
pubmed: 28402773
Ophthalmology. 1986 Sep;93(9):1183-7
pubmed: 3101021
Diabetes Care. 1994 Nov;17(11):1281-9
pubmed: 7821168
Diabetologia. 1994 Mar;37(3):278-85
pubmed: 8174842
Neurology. 1993 Apr;43(4):817-24
pubmed: 8469345

Auteurs

Katherine A Sauder (KA)

Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA. Electronic address: katherine.sauder@ucdenver.edu.

Jeanette M Stafford (JM)

Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Elizabeth J Mayer-Davis (EJ)

Department of Nutrition, University of North Carolina, Chapel Hill, NC, USA.

Elizabeth T Jensen (ET)

Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Sharon Saydah (S)

Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Amy Mottl (A)

Division of Nephrology and Hypertension, University of North Carolina School of Medicine, Chapel Hill, NC, USA.

Lawrence M Dolan (LM)

Division of Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

Richard F Hamman (RF)

Department of Epidemiology, Colorado School of Public Health, Aurora, CO, USA.

Jean M Lawrence (JM)

Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.

Catherine Pihoker (C)

Department of Pediatrics, University of Washington, Seattle, WA, USA.

Santica Marcovina (S)

Northwest Lipid Research Laboratory, University of Washington, Seattle, WA, USA.

Ralph B D'Agostino (RB)

Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Dana Dabelea (D)

Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA; Department of Epidemiology, Colorado School of Public Health, Aurora, CO, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH